The European Commission has approved a label expansion for Kaftrio in combination with Kalydeco (ivacaftor) to treat…
Articles by Steve Bryson, PhD
Evidence of immune dysfunction — elevated levels of immune cells and immune-related molecules — were found in the lungs of…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Porosome Therapeutics’ new treatment strategy for…
Nearly 80% of men with cystic fibrosis (CF) who underwent fertility treatment due to a lack of sperm became…
Prenatal Trikafta treatment of three fetuses with cystic fibrosis (CF) for an intestinal blockage called meconium ileus resulted…
The U.S. Food and Drug Administration (FDA) has expanded the approval of Trikafta for people with cystic fibrosis…
Infants with cystic fibrosis (CF) have alterations to the nasal microbiome — the community of microbes that live in…
About half of people with cystic fibrosis (CF) had breathing difficulties during sleep a year after a lung transplant,…
Treatment with Kalydeco (ivacaftor) reduces the number of Pseudomonas aeruginosa bacteria in the lungs during an acute infection, but…
Researchers discovered a molecule that may help deliver gene therapies to cells in the thick mucus environment of the…